Interleukin-34 in rheumatoid arthritis: Potential role in clinical therapy

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 5, 2015, Pages 7809-7815

  Zhang, Fangze ^a   Ding, Rui ^a   Li, Ping ^a   Ma, Cuili ^a   Song, Ding ^a   Wang, Xuetong ^a   Ma, Tianjiao ^a   Bi, Liqi ^a  

^a CHINA JAPAN UNION HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

IL 34; IL 6; IL 8; MMP 3; Rheumatoid arthritis; TNF

Indexed keywords

C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; ETANERCEPT; INTERLEUKIN 34; INTERLEUKIN 8; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CONTROLLED STUDY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; RHEUMATOID ARTHRITIS;

EID: 84937046461     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. [1] Scott DL, Wolfe F and Huizinga TW. Rheumatoid arthritis. Lancet 2010; 376: 1094-1108.
2. [2] Lin H, Lee E, Hestir K, Leo C, Huang M, Bosch E, Halenbeck R, Wu G, Zhou A, Behrens D, Hollenbaugh D, Linnemann T, Qin M, Wong J, Chu K, Doberstein SK and Williams LT. Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. Science 2008; 320: 807-811.
3. [3] Clavel G, Thiolat A and Boissier MC. Interleukin newcomers creating new numbers in rheumatology: IL-34 to IL-38. Joint Bone Spine 2013; 80: 449-453.
4. [4] Tian Y, Shen H, Xia L and Lu J. Elevated serum and synovial fluid levels of interleukin-34 in rheumatoid arthritis: possible association with disease progression via interleukin-17 production. J Interferon Cytokine Res 2013; 33: 398-401.
5. [5] Moon SJ, Hong YS, Ju JH, Kwok SK, Park SH and Min JK. Increased levels of interleukin 34 in serum and synovial fluid are associated with rheumatoid factor and anticyclic citrullinated peptide antibody titers in patients with rheumatoid arthritis. J Rheumatol 2013; 40: 1842-1849.
6. [6] Chemel M, Le Goff B, Brion R, Cozic C, Berreur M, Amiaud J, Bougras G, Touchais S, Blanchard F, Heymann MF, Berthelot JM, Verrecchia F and Heymann D. Interleukin 34 expression is associated with synovitis severity in rheumatoid arthritis patients. Ann Rheum Dis 2012; 71: 150-154.
7. [7] Chen Z, Buki K, Vaaraniemi J, Gu G and Vaananen HK. The critical role of IL-34 in osteoclastogenesis. PLoS One 2011; 6: e18689.
8. [8] Hwang SJ, Choi B, Kang SS, Chang JH, Kim YG, Chung YH, Sohn DH, So MW, Lee CK, Robinson WH and Chang EJ. Interleukin-34 produced by human fibroblast-like synovial cells in rheumatoid arthritis supports osteoclastogenesis. Arthritis Res Ther 2012; 14: R14.
9. [9] Lee A, Qiao Y, Grigoriev G, Chen J, Park-Min KH, Park SH, Ivashkiv LB and Kalliolias GD. Tumor necrosis factor alpha induces sustained signaling and a prolonged and unremitting inflammatory response in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2013; 65: 928-938.
10. [10] Yarilina A, Xu K, Chan C and Ivashkiv LB. Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors. Arthritis Rheum 2012; 64: 3856-3866.
11. [11] Han W, Xiong Y, Li Y, Fang W, Ma Y, Liu L, Li F and Zhu X. Anti-arthritic effects of clematichinenoside (AR-6) on PI3K/Akt signaling pathway and TNF-alpha associated with collagen-induced arthritis. Pharm Biol 2013; 51: 13-22.
12. [12] Kanbe K, Chiba J and Nakamura A. Inhibition of JNK in synovium by treatment with golimumab in rheumatoid arthritis. Rheumatol Int 2014; 34: 125-130.
13. [13] Macias I, Garcia-Perez S, Ruiz-Tudela M, Medina F, Chozas N and Giron-Gonzalez JA. Modification of pro-and antiinflammatory cytokines and vascular-related molecules by tumor necrosis factor-a blockade in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 2102-2108.
14. [14] Sun S, Bay-Jensen AC, Karsdal MA, Siebuhr AS, Zheng Q, Maksymowych WP, Christiansen TG and Henriksen K. The active form of MMP-3 is a marker of synovial inflammation and cartilage turnover in inflammatory joint diseases. BMC Musculoskelet Disord 2014; 15: 93.
15. [15] Nishimoto N and Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2006; 2: 619-626.
16. [16] Van Snick J. Interleukin-6: an overview. Annu Rev Immunol 1990; 8: 253-278.
17. [17] Qu N, Xu M, Mizoguchi I, Furusawa J, Kaneko K, Watanabe K, Mizuguchi J, Itoh M, Kawakami Y and Yoshimoto T. Pivotal roles of T-helper 17-related cytokines, IL-17, IL-22, IL-23, in inflammatory diseases. Clin Dev Immunol 2013; 2013: 968549.
18. [18] Kraan MC, Patel DD, Haringman JJ, Smith MD, Weedon H, Ahern MJ, Breedveld FC and Tak PP. The development of clinical signs of rheumatoid synovial inflammation is associated with increased synthesis of the chemokine CXCL8 (interleukin-8). Arthritis Res 2001; 3: 65-71.
19. [19] Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB and van Riel PL. Mod ified disease activity scores that include twenty-eight-joint counts. Development and vali-dation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-48.
20. [20] Gu J. Rheumatoid Arthritis. Internal Medicine. 7th edition. Beijing: People’s medical publishing house; 2008. pp. 848-855.
21. [21] Avdeeva AS, Aleksandrova EN, Novikov AA, Cherkasova MV, Panasyuk EY and Nasonov EL. [Relationship of the clinical efficiency of tocilizumab therapy to the serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis]. Ter Arkh 2013; 85: 24-29.
22. [22] Li L, Cai B, Liao J, Yang B, Huang Z and Wang L. [Clinical value of serum matrix metalloproteinase-3 in evaluating joint destruction and therapeutic effect in rheumatoid arthritis patients]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2013; 29: 966-969.
23. [23] Shimamoto K, Ito T, Ozaki Y, Amuro H, Tanaka A, Nishizawa T, Son Y, Inaba M and Nomura S. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis. J Rheumatol 2013; 40: 1074-1081.
24. [24] Alessandri C, Priori R, Modesti M, Mancini R and Valesini G. The role of anti-cyclic cytrullinate antibodies testing in rheumatoid arthritis. Clin Rev Allergy Immunol 2008; 34: 45-49.
25. [25] Fathi NA, Ezz-Eldin AM, Mosad E, Bakry RM, Hamed HB, Ahmed S, Mahmoud M, Rashed HA and Abdullah F. Diagnostic performance and predictive value of rheumatoid factor, anti-cyclic-citrullinated peptide antibodies and HLA-DRB1 locus genes in rheumatoid arthritis. Int Arch Med 2008; 1: 20.
26. [26] Syversen SW, Goll GL, van der Heijde D, Landewe R, Gaarder PI, Odegard S, Haavardsholm EA and Kvien TK. Cartilage and bone biomarkers in rheumatoid arthritis: prediction of 10-year radiographic progression. J Rheumatol 2009; 36: 266-272.